The Latest Cardiac and Vascular News
New CPT I Code, OPPS and MPFS Decisions Recognize Significant Clinical Value Across Care Settings BOSTON–(BUSINESS WIRE)–Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ […]
TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.
Novel membrane-based PFO Sealing system designed to address limitations of current stroke prevention devices NEW YORK, Dec. 3, 2025 /PRNewswire/ — Recross Cardio Inc., a structural heart company pioneering next-generation membrane sealing technology, today announces the first clinical…
WASHINGTON—The Society for Cardiovascular Angiography & Interventions (SCAI) and Cardiovascular Research Technologies (CRT) today announce a new collaboration to elevate the field of interventional cardiology through shared education programming, legislative activities, and future research initiatives. As part of the collaboration, CRT is offering SCAI members discounted registration for CRT 2026, […]
DENVER–(BUSINESS WIRE)–Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added lesion-level reporting, discuss new clinical research findings, and provide guidance on the […]
SYDNEY, Nov. 24, 2025 (GLOBE NEWSWIRE) — AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise that it has completed its clinical validation for its heart failure clinical decision support software (“EchoSolv HF”) in collaboration with the Mayo Clinic Platform (“MCP”), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software (refer ASX Announcement 1 July 2025).
IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an expanded cohort of 700 patients from the ALIGN-AR pivotal trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR). These results were published in The Lancet and simultaneously presented as part of the Late-Breaking Clinical Trial sessions at PCR London Valves.
TeraRecon AV™ delivers advanced imaging visualization with AI-driven automations, enhancing clinician diagnostic precision and patient care while reducing manual efforts. It introduces advanced structural heart imaging simulations in a single solution, including Transcatheter Tricuspid Valve Replacement (TTVR), Transcatheter Mitral Valve Repair (TMVR), and Advanced Left Atrial Appendage (LAA) procedures, along […]
The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care. WASHINGTON, Nov. 19, 2025 /PRNewswire/ — The second issue of the Journal of Cardiac Failure-Intersections, online now, delivers a diverse…
LIÈGE, Belgium & BEDFORD, Mass.–(BUSINESS WIRE)–CryoTherapeutics, a medical device company developing minimally invasive localized cryotherapy for the treatment of coronary artery disease, today announced a unique three-way collaboration with SpectraWAVE, an innovator in intravascular imaging and physiology and the Cardiovascular Research Foundation (CRF), the global leader in cardiovascular research, to […]
